• Explore /
  • Poster
  • / KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

Josep Tabernero

Josep Tabernero

Vall d’Hebron University Hospital, Barcelona, Spain

Josep Tabernero , Yung-Jue Bang , Charles S. Fuchs , Atsushi Ohtsu , Uma Kher , Baohoang Lam , Minori Koshiji , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02494583

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS185)

DOI

10.1200/jco.2016.34.4_suppl.tps185

Abstract #

TPS185

Poster Bd #

O11

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: Yelena Y. Janjigian